Skip to main content

Table 2 Comparison of clinicopathological features between fusion-positive MLH1 hypermethylated colorectal cancers, and fusion-negative MLH1 hypermethylated colorectal cancers

From: Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing

  MLH1me+ with fusion
(n = 22)
MLH1me+ without fusion
(n = 69)
P#
Age, median, years 72 62 0.013
Gender, n(%)
 Female 13 (59) 37 (54) 0.806
 Male 9 (41) 32 (46)  
Tumor location, n(%)
 Hepatic flexure 13 (59) 8 (12)  < 0.001
 Other sites of large intestine 9 (41) 61 (78)  
  Ileocecum 1 (5) 20 (29)  
  Ascending colon 5 (23) 16 (23)  
  Transverse colon 1 (5) 6 (9)  
  Splenic flexure 1 (5) 2 (3)  
  Descending colon 1 (5) 5 (7)  
  Rectosigmoid 0 12 (17)  
AJCC stage, n(%)
 I 0 (0) 4 (5) 0.925
 II 15 (68) 42 (61)  
 III 7 (32) 20 (29)  
 IV 0 (0) 2 (3)  
Presence of poor differentiated area, n(%)
 Yes 13 (59) 18 (26) 0.009
 No 9 (41) 51 (74)  
Mucinous differentiation, n(%)
 Yes 9 (41) 25 (36) 0.801
 No 13 (59) 44 (64)  
Lymphovascular invasion, n(%)
 Yes 10 (45) 23 (33) 0.445
 No 12 (55) 46 (67)  
Perineural invasion, n(%)
 Yes 3 (14) 5 (7)  
 No 19 (86) 64 (93)  
  1. MLH1me+, MLH1 hypermethylated
  2. #P values were based on Chi-square test, Fisher’s exact test, or Mann–Whitney tests, whenever appropriate. All statistical tests were two-sided